Letrozole is a non-steroidal aromatase inhibitor. It reduces the conversion of androgens into estrogens, lowering circulating estrogen levels.
Its principal established application is hormone-receptor-positive breast cancer, particularly in postmenopausal patients. Depending on the clinical setting, it may be used after other treatments or as part of longer-term hormonal therapy.
The supplied tablets specify 2.5mg. Reduced estrogen can contribute to hot flashes, joint symptoms, and loss of bone mineral density, making clinical monitoring relevant during treatment.
Reviews
There are no reviews yet.